LB-100 selectively inhibits a cellular enzyme that regulates tumor biology and immune visibility, aiming to convert immunologically cold tumors into ones susceptible to T-cell attack when used alongside checkpoint inhibitors.

LIXTE has advanced LB-100 into clinical development in collaboration with academic and research institutions, designing early-phase trials to evaluate safety, optimal dosing and preliminary efficacy in cancer patients.